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 Invasive fungal infections remain a leading cause of morbidity and mortality in the 
world, accounting for ~1.5 million deaths each year. Currently available treatments have 
important limitations, and the emergence of pathogen resistance is further weakening 
the clinical efficacy of most of these medicines. Amphotericin B (AmB) remains the last 
line of defense in treating these infections. Remarkably, this potent and broad-spectrum 
fungicidal agent has evaded pathogen resistance despite clinical utilization for more 
than half a century. However, the clinical efficacy of AmB is limited by its extreme 
toxicity, particularly to the kidneys. Guided by our lab’s recent advances in 
understanding the primary mechanism by which AmB kills both yeast and human cells, 
we have identified a promising new derivative of this natural product: C2’epiAmB. This 
derivative is dramatically less-toxic than AmB in primary human renal cells, mice, and 
rats at the highest doses. With this exciting direction, efficient access to large amount of 
C2’epiAmB are necessary from both a discovery and application standpoint. Therefore, 
development of a chemoenzymatic synthesis to C2’epiAmB would be imperative. We 
set out to determine an effective strategy to detect an active glycotransferase using 
AmB as a test substrate. AmphDI is the reversible glycotransferase responsible for 
glycosylation of the aglycone acceptor AmdeB with GDP-mycosamine in the 
biosynthesis of AmB. Using the reverse glycosylation reaction, we identified robust 
detecting of deglycosylation product amphoternolide (AmdeB) using AmB as starting 
material. Unfortunately, C2’epiAmB was not accepted by AmphDI and would therefore 
require generating a large library of mutants to be screened. The deglycosylation 
reaction leads to low conversion, which contrasts with the 4-fold increase seen in the 
glycosylation reaction seen in previous reports. Importantly this glycosylation was used 
with GDP-mannose, the stereochemical surrogate of natural GDP-mycosamine. We 
decided to use the stereochemical surrogate of GDP-C2’epimycosamine, GDP-glucose, 
as the sugar donor to glycosylate AmdeB. Under our conditions, GDP-glucose like 
C2’epiAmB was not accepted by AmphDI. Therefore, an AmphDI enzyme that 
glycosylates AmdeB with GDP-glucose should also accept GDP-C2’epimycosamine. 
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Using the same assay, the deglycosylation and glycosylation reactions should 


























I would first and foremost would like to thank and acknowledge my late dear friend and 
mentor Anuj Khandelwal. His passion for science was unquestionable as well as his will 
to mentor younger students. He will be truly missed, not only from myself but the entire 
Burke group and the U of I chemistry department. I would like to acknowledge and 
thank my PI, Prof. Martin D. Burke, for all his guidance, energy and unwavering 
enthusiasm he brought to every project and meeting driving forward his group and 
myself. I would like to especially thank my colleague and friend Jiabao Zhang who has 
been a pleasure to work with these past three years. He has given me a tremendous 
amount of support thorough my time here. I would like to thank Anna Santamaria and 
Jenn Hou who helped me develop and learn all the biological assays presented herein. I 
would also like to thank the entire Burke group (both current and former) for the 
numerous times they have supported and guided me. I would like to acknowledge Sherif 
Elshahawi and Jon Thorson at the University of Kentucky for our initial collaboration for 
generating the first AmphDI mutant library, expressing and isolating AmphDI, and for 
their insight developing the enzyme project. I would like to acknowledge Mr. Sun Furong 
of the Mass Spectrometry Facility at University of Illinois for running and helping 
develop the mass spectrometry conditions for identifying amphotericin B and 
amphoternolide. I would also like to acknowledge our new and ongoing collaboration 
between Huimin Zhao’s and Satish Nair’s lab to develop a way to make kilograms 
quantities of C2’epiAmB. Lastly, I would like to acknowledge my loving and supportive 



































TABLE OF CONTENTS 
 
Chapter 1: The Emergence of Invasive Fungal Infections .....................................1 
Chapter 2: Synthesis and Biological Evaluation of C2’epiAmB .............................6 















Chapter 1: The Emergence of Invasive Fungal Infections 
Invasive fungal infections (IFIs) have emerged as one of the leading causes of human 
mortality (~1.5 million deaths/year) and morbidity with a survival rate of only 50%.1–4 In 
the clinic, a diverse range of pathogenic fungi are commonly found and are challenging 
to identify prior to initiating treatment. These invasive fungal infections are largely 
caused by two common genera of fungal pathogens: Candida and Aspergillus.5–14 In the 
healthiest of patients, treatment for invasive candidiasis has a limited success rate (50-
70%) and has an attributable mortality of 20-30%.15–17 In addition, Candida species are 
the 4th most common pathogen isolated in all bloodstream infections.18 The incidence 
of invasive aspergillosis due to A. fumigatus has increased three-fold in the last 
decade15 and its mortality has risen by over 300%.19 Current therapy for invasive 
aspergillosis has a lower treatment success rate of 40-50%.20,21 and is consistently a 
leading killer in immunocompromised patients.22,23 Invasive mold infections (fusariosis, 
scedosporosis, and mucromycosis) have even higher mortality rates with no effective 
therapeutic options.24,25 The current guideline-recommended first line therapeutic for 
invasive aspergillosis, as well as most other invasive mold infections, is the triazole 
antifungal voriconazole.26,27 However, pan-triazole resistance in Aspergillus is as high 
as 30% in some locations and amongst certain high-risk patient groups.28 Many antiviral 
and antibacterial agents are highly selective for pathogen vs. human targets and can be 
safely administered at high doses to treat the most serious infections. In contrast, there 
is substantial homology between most targets in eukaryotic pathogens and those in 
their human counterparts consistent with more recent evolutionary divergence. As a 
result, most current antifungals have much narrower selectivity windows, and “high-
dose” infection eradication strategies are not possible. For example, many azole 
antifungals cross-react with human P450 enzymes, leading to clinically significant 
detrimental drug-drug interactions.29–32 The echinocandin antifungals (e.g. caspofungin) 
are theoretically more selective because they target the fungal cell wall, but can still 
have significant dose-limiting side effects, particularly in severely ill patients. Moreover, 
resistance to the echinocandins has emerged in multiple fungi and is increasing.33–38 
Recognizing this lack of effective treatments, the Infectious Diseases Society of 
America highlighted A. fumigatus as one of only six pathogens where a “substantive 
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breakthrough is urgently needed.”39  To achieve this “breakthrough”, Amphotericin B 
(AmB) serves as an exceptionally promising starting point, because this drug has potent 
and dose-dependent14,40,41 fungicidal activity against a broad range of fungal pathogens 
and has evaded resistance for over half a century.42 The fungicidal, in contrast to the 
fungistatic, activity of AmB is essential in immunocompromised patients which lack a 
robust immune system to help clear an infection. Broad antifungal activity is especially 
important in critically ill patients when the identity of the pathogen is unknown and 
immediate empirical therapy is required. Unfortunately, AmB is exceptionally toxic which 
limits its use to low-dose protocols that often fail to eradicate disease. An AmB 
derivative that retains potent, broad spectrum, and resistance-evasive fungicidal activity 
but lacks dose-limiting toxicities would enable an enchanced treatment regimen with 
improved clinical efficacy.  
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Figure 1.  a: Chemical structures of amphotericin B, ergosterol - the primary fungal sterol, and 
cholesterol - the primary human sterol. b: Two-step “Sterol Sponge” model for the cytocidal mode 
of action for AmB. 
Chapter 2: Synthesis and Biological Evaluation of C2’epiAmB 
More than half a century of unsuccessful attempts to develop a clinically viable less 
toxic derivative of AmB were fundamentally misguided by the widely accepted 
mechanistic model which asserts that AmB primarily kills cells by permeabilizing 
membranes.1–29 The Burke group developed frontier synthetic methods to efficiently 
modify complex natural products.30–34 Enabled by these developments, Gray et al. and 
Wilcock et al. alternatively discovered that AmB primarily kills fungal and human cells by 
binding ergosterol and cholesterol, respectively (Figure 1a); channel formation is not 
required.35–37 Our data are consistent with a “sterol sponge” model (Figure 1b), whereby 
AmB self-assembles into a large extramembranous aggregate and rapidly extracts 












To probed its 
predicted role 
in sterol binding, we synthetically deleted the hydroxyl group at the C2’ position on the 
mycosamine appendage.36 The resulting derivative, C2’deOAmB (Figure 2a), was found 
to bind ergosterol, within the detection limits of isothermal titration calorimetry (ITC), but 
not cholesterol (Figure 2c). Consistent with the sterol sponge model, this derivative 
retained good activity against yeast but most importantly, was nontoxic to human red 
blood cells and primary human renal epithelial cells (Figure 2b). 2-Deoxy glycosides are 







Figure 2. Chemical Structures, biological and biophysical properties of AmB, 
AmdeB, C2’deOAmB, and C2’epiAmB. 
 
has precluded its 
development. However, these 
findings led us to a predictive 
model for guiding the 
development of more 
synthetically accessible 
derivatives with similar 
selectivity profiles. 
Specifically, to rationalize the 
selective toxicity of 
C2’deOAmB for fungal vs. 
human cells, we proposed a 
model in which the C2’-OH 
stabilizes a conformer of AmB 
that readily binds both 
ergosterol and cholesterol. 
We hypothesized that 
deletion of this hydroxyl group 
favors a shift to a different conformer or set of conformers which retain the capacity to 
bind ergosterol but not the more sterically bulky cholesterol. Alternatively stated, this 
model suggests that deletion of the C2’OH of AmB causes a small molecule-based 
allosteric effect that results in ligand-selective binding. In a recent high-resolution X-ray 
crystal structure of N-iodoacyl AmB43,44, there is a prominent water-bridged hydrogen-
bond between the hydroxyl groups at C2’ and C13 that may serve to stabilize a 
particular conformation of the mycosamine appendage relative to the polyene macrolide 
core. This observation combined with our previous findings that the mycosamine 
appendage is critical for binding both ergosterol and cholesterol37 and observations by 
SSNMR of direct intermolecular contacts between the AmB polyene and the A/B rings 
of ergosterol38, allowed us to propose a specific structural model for both AmB-sterol 
complexes consistent with all of our data. Guided by this model, we predicted a simple 




Figure 3. 11-step synthesis of C2’epiAmB from AmB.  
 
 
Figure 4. Toxicity of AmB deoxycholate and 
C2’epiAmB deoxycholate in mice by percent 
lethality.   
eliminate the water-bridged C2’OH-C13OH interaction and cause a shift in the 
orientation of the mycosamine appendage similar to that predicted in C2’deOAmB. We 
expected that the resulting derivative, C2’epiAmB (Figure 2a), would selectively bind 
ergosterol and exert cytocidal action against fungal but not human cells. 
Synthesis and Biological Evaluation of C2’epiAmB  
The Burke group utilized a 
practical 11-step synthesis 
of C2’epiAmB using a 
frontier site-selective 
acylation method to 
prepared >100mg of 
C2’epiAmB (Figure 3).31,45 
They then determined its 
sterol binding and cell 
killing activities. As 
predicted, like 
C2’deOAmB, C2’epiAmB was found by ITC to bind ergosterol but not (detectably) 
cholesterol, and, most importantly, to kill fungal but not human cells (Figure 2a). Moving 
to higher organisms, the Burke group formulated C2’epiAmB as the corresponding 
deoxycholate complex, and evaluated this derivative head-to-head with AmB-
deoxycholate for toxicity and efficacy in mice 
(Figure 4). From this exciting data generated from 
prior colleagues, we set out to synthesize this 
promising derivative for future studies. Collectively 
we had synthesized ~250mg of material. We aimed 
to directly compare the toxicity of C2’epiAmB with 
the clinically used AmBisome. Jiabao Zhang and 
Tim Fan directly compared the toxicity of 
C2’epiAmB to AmBisome®, a liposomal formulation 
of AmB that is widely used clinically because it is 




Figure 5. Toxicity of AmBisome® compared directly with C2’epiAmB, as 
judged by renal genotoxicity biomarkers. Animals were treated with three 
compounds of interest and their respective vehicle. After 24h, the animals 
were sacrificed following the harvest of the kidneys. The kidneys were then 
homogenized and extracted RNA, quantification of genotoxicity markers 
(Kim1, Lcn2, Timp1 and Spp1) expression was characterized by RT-PCR 
and normalized to D5W (5% dextrose in water) control. 
 
 
Figure 6. Left: Growth curve of Candida albicans against C2’epiAmB and pre-complexed C2’epiAmB: Erg. Right: Growth Curve 
of Candida albicans against AmB and pre-complexed AmB:Erg. 
 
deoxycholate) (Figure 5).46 Consistent with literature precedent,47 he confirmed that 
AmBisome® shows significant toxicity in mice at 48 mg/kg as judged by state-of-the art 
renal genotoxicity biomarkers. Next, he alternatively injected mice with the same high 
dose (48 mg/kg) of C2’epiAmB-deoxycholate and observed no significant elevations in 
these same biomarkers. Thus, C2’epiAmB is significantly less toxic than AmBisome® in 
mice. In each case, C2’epiAmB is non-toxic to human red blood cells, primary human 
renal epithelial cells, and mice 
up to the highest dose tested. 
These results are consistent 
with our finding that, within 
limits of detection of all of our 
experiments, C2’epiAmB does 
not bind cholesterol. 
Providing strong evidence for 
the sterol sponge mechanism, 
we previously demonstrated 
that the antifungal activity of 
AmB is mitigated via pre-
complexing the AmB sterol 
sponge with ergosterol. We proposed pre-complexing impedes its capacity to extract 
ergosterol from yeast cells.38 In a follow-up study performed in collaboration with Susan 
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Lindquist at MIT, we showed that this mechanism is inherently evasive to clinical 
resistance, because mutations in the ergosterol biosynthetic pathway causes loss of 
pathogenicity.44 To test whether C2’epiAmB primarily kills cells via the same sterol 
sponge mechanism, we similarly pre-complexed C2’epiAmB with ergosterol in a 1:5 
molar ratio and assessed the activity of the complex against  wild-type (WT) C. albicans. 
By determining growth via optical density at 600nm, we observed the same reduction in 
potency once ergosterol is pre-complexed with AmB and C2’epiAmB respectively 
(Figure 6, left).38 Specifically, when pre-complexed with ergosterol, there is a 16 and 8-
fold reduction in potency for AmB and C2’epiAmB respectively (Figure 6). Therefore, 
C2’epiAmB similarly kills yeast primarily via sterol binding, and, by extension, we expect 
C2’epiAmB will have a similar barrier to fungal resistance that has been observed for 
the past 50+ years with AmB. 
However, C2’epiAmB is synthetically challenging to access on the gram scale 
and would not be able to meet the global demand for AmB. Moreover, the subsequent 
deprotections and functional group interconversions are tedious and require labor 
intensive HPLC purifications after each step. Therefore, constructing a chemoenzymatic 
synthesis that utilizes AmB as a substrate to produce the desired C2’epiAmB via a 
sugar exchange or glycosylation of aglycone would overcome this synthetic barrier and 
provide robust and scalable access to these derivatives.  
Author Contributions 
For scientific contributions, Jiabao Zhang completed the synthesis of C2’epiAmB from 
AmB to generate ~250mg of C2’epiAmB (Figure 3). Jiabao and Tim Fan DVM, PhD 
(UIUC) determined the toxicity of AmB, C2’epiAmB, and AmBisome® in mice with RT-
PCR for expression and quantification of renal genotoxicity biomarkers (Figure 5).46  
Anthony Sotelo was responsible assessing the in vitro biological activity of AmB, and 
C2’epiAmB against various strains of Candida and Aspergillus. Anthony also pre-
complexed ergosterol and AmB or C2’epiAmB respectively for their in vitro activity 
against Candida albicans (Figure 6).  
Material and Methods 
Commercial reagents were purchased from Sigma-Aldrich, Alfa Aesar, Oakwood, and 
Fischer Scientific and used without further purification unless otherwise noted. Solvents 
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were purified by passage through packed columns by the method of Pangborn et al.53 
(THF, Et2O, CH3CN, CH2Cl2, benzene, toluene, DMSO, DMF, CH3OH). Water was 
used from a Millipore (Billerica, MA) Milli-Q water purification system. Triethylamine and 
diisopropylethylamine were freshly distilled under an atmosphere of nitrogen on CaH2. 
(±)-10-camphorsulfonic acid was recrystallized from ethyl acetate.  
General Experimental Procedures 
All reactions were performed in flame- or oven-dried glassware (60°C) under an 
atmosphere of dry nitrogen or argon unless otherwise stated. Reactions were monitored 
by analytical thin layer chromatography (TLC) on Merck silica gel 60 F254 plates 
(0.25mm) using the described solvent system. Compounds were visualized by exposure 
to UV light at 254nm or by ceric ammonium molybdate (CAM) stain by heating with a 
Varitemp heat gun. Flash column chromatography was performed using Merck silica gel 
60 (230-400mesh).  
Structural Analysis 
1H NMR spectra were recorded at ambient temperature using one of the following 
instruments: Craver B500 (500MHz). Varian Unity 500 (500MHz), Varian VXR 500 
(500MHz), or Varian Unity Inova 500NB (500MHz). Chemical shifts are reported in parts 
per million (ppm) downfield from tetramethylsilane and referenced to residual protium in 
the NMR solvent (CDCl3, δ=7.26; (CD3)2CO, δ=2.05, center line). Spectral data are 
represented as follows: chemical shift, multiplicity (s= singlet, d= doublet, t= triplet, q= 
quartet, quin= quintet, sext= sextet, dd= double of doublets, dt= doublet of triplets, ddd= 
doublet of doublet of doublets, m= multiplet, b= broad, app= apparent), coupling 
constant (J) in Hertz (Hz), and integration. 13C NMR spectra were recorded at ambient 
temperature using one of the following instruments: Craver B500 (125MHz). Varian 
Unity 500 (125MHz), or Varian VXR 500 (500MHz). Chemical shifts are reported in ppm 
downfield from tetramethylsilane and referenced to carbon resonances in the NMR 
solvent (CDCl3, δ=77.16; (CD3)2CO, δ=29.84, center line). High resolution mass spectra 
(HRMS) were acquired by Mr. Furong Sun at the University of Illinois School of 
Chemical Sciences Mass Spectrometry Laboratory. Data are reported in the form of 
m/z.  
Purification of AmB and its Derivatives 
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Large scale preparatory purification of AmB and its derivatives were carried out by 
preparative HPLC purification using an Agilent 1200 series instrument equipped with 
a Waters Sunfire Prep C18 OBD 5µm, 50x250mm column at 50ml/min with detection 
at 406 and 383nm with an eluent of acetonitrile and 15mM ammonium acetate in 
water unless otherwise indicated. The purity of AmB and its derivatives was 
determined by HPLC analysis using an Sunfire C18 5µm, 4.6x150mm column or an 
Agilent Eclipse XDB-C18 5µm, 4.6x150mm column with detection at 406 and 383 
nm with an eluent of acetonitrile and 15mM ammonium acetate unless otherwise 
indicated.   
Synthesis of C2’epiAmB 
The synthesis of C2’epiAmB was performed as previously described.31,45  
Yeast Media Conditions 
YPD: For 1L of YPD media, 20g of bactopeptone and 10g of yeast extract was added 
into approximately 700-800ml of milli-Q H2O. This solution was then autoclaved for 
30mins. After autoclaving, 50ml of a 40% sterile dextrose solution was added per L of 
media and the remaining volume was filled with sterile milli-Q H2O. For solid media, 15g 
per liter of agar was added prior to autoclaving.  
SB: For 1L of solid Sabouraud media, 20g of mycological peptone (Sigma) and 50ml of 
a 40% sterile dextrose solution was added into approximately 900ml of milli-Q H2O. The 
solution was then acidified to pH=5.6 and then autoclaved for 30mins. For solid media, 
15g of Sabouraud agar (Difco) was added.  
RPMI: For 1L of RPMI media, 1 package of powdered RPMI-1640 (Sigma, Product No. 
R6504) w/ L-glutamine and without sodium bicarbonate was added into 1L of milli-Q. 
The solution was then buffered with MOPS to a final concentration of 0.165M (pH=7.0) 
and supplemented with 10% FBS unless otherwise indicated (Gibco Product No. 
A31605).44    
Growth Conditions for Candida strains 
Candida strains were maintained as frozen 15-20% glycerol stocks at -80°C. In a 
laminar flow hood, Candida strains were streaked onto solid YPD agar plates utilizing 
sterile inoculating loops. The plates were cultivated upside down in a 37°C incubator for 
24-48 hours until visible single colonies units formed. The plates were then wrapped in 
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parafilm and kept upside down in a 4°C fridge. Candida strains were subculture with 
inoculating a single colony into 50ml of YPD media. The inoculum was incubated at 
30°C at 200rpm  for at least 12hrs.  
Growth Conditions for Aspergillus strains 
Aspergillus strains were maintained as frozen 15-20% glycerol stocks at -80°C. In a 
laminar flow hood, Aspergillus cell strains were pipetted onto solid SB agar plates 
utilizing sterile tips until the suspension adequately cover the surface of the plate. The 
plates were cultivated upside down in a 37°C incubator for 24-48 hours until it 
sporulated throughout the entire surface of the plate. The plates were then wrapped in 
parafilm and kept upside down in a 4°C fridge. 
In vitro Activity of Pre-Complexed of AmB and C2’epiAmB 
The broth microdilution assay for determining the minimum inhibitory concentration 
(MIC) of Candida albicans was adapted from the Clinical and Laboratory Standards 
Institute document M27-A3.52 50ml of YPD media was inoculated with Candida albicans 
and incubated overnight at 30°C (200rpm) in a shaker incubator. The cell suspension 
was then diluted into RPMI liquid media supplemented with 50ml of sterile 40% 
dextrose to 1.0x105 cfu/ml by hemocytometer. 195µL aliquots of the RPMI cell 
suspension was then added into a sterile Falcon Microtest 96-well plate in triplicate. 
Ergosterol was prepared as a stock solution (4mg/ml in CHCl3) where chloroform was 
removed by a gentile stream of nitrogen gas. Residual solvent was removed under high 
vacuum overnight. A DMSO solution of 640 µM AmB or C2’epiAmB was then added to 
solid ergosterol (1:5 mol ratio AmB:Erg).38 The resulting solution was gently vortexed 
and then heated to 80°C for 1 hour in an aluminum heat block to allow ergosterol to fully 
dissolve and subsequently allow to cool to room temperature. Compounds were 
prepared as 640µM DMSO solutions and serially diluted to the following concentrations: 
640, 320, 160, 80, 40, 20, 10, 5, 2.5, and 1.25µM. 5µL aliquots of each solution were 
added to the 96-well plate in triplicate with each column representing a different 
concentration of the test compound. The concentration of DMSO in well was 2.5% and 
a control well to confirm viability using 2.5% DMOS was performed in triplicate. This 40-
fold dilution gave the following concentrations: 16, 8, 4, 2, 1, 0.5, 0.25, 0.125. 0.0625, 
0.03125µM. Plates were covered and incubated at 37°C for 24 hours prior to analysis. 
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The MIC was determined to be the concentration of compound that resulted in no visible 
growth of yeast. Growth curves were obtained by UV-Vis OD600.  
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Figure 8. Chemoenzymatic deglycosylation of AmB with AmphDI to aglycone AmdeB.  
Chapter 3: Methods for Determining Active AmphDI Enzymes 
For Amphotericin B, the mycosamine sugar is biosynthetically installed through the 
glycosylation of an aglycone amphoternolide (AmdeB) with an activated guanosine 
diphosphate mycosamine sugar (GDP-mycosamine) by the glycosyltransferase AmphDI 
(Figure 7).1 The Thorson group has characterized this enzyme in vitro and 
demonstrated that the glycosyltransferase AmphDI is reversible and can readily accept 
mannose derived sugar donors.2 GDP-sugar donors are chemoenzymatically prepared 
by the enzyme OleD Loki.3 In collaboration with the Thorson lab, prior colleagues have 
successfully synthesized the activated and stable GDP-C2’epimycosamine sugar donor. 
With access to stable GDP-sugar donor and aglycone acceptor amphoternolide 
(AmdeB), C2’epiAmB has emerged as a prime candidate for chemoenzymatic 
synthesis.   However, we found that AmphDI does not accept GDP-C2’epimycosamine, 
a glucose derived sugar donor, as a substrate. Therefore, we aimed to identify a 
permissive mutant of AmphDI that tolerates this stereochemical perturbation.  
Previously, the Thorson group has shown that mutations in glycosyltransferases may 
produce a more 
promiscuous enzyme 
that manifests a broader 
substrate scope than 
the wild-type enzyme 
itself.4–7 Since then, this 
strategy has been 
successfully applied on other natural products.8–22 Thus, through directed evolution, 
iterative libraries of mutant AmphDI enzymes can be generated and screened in pursuit 
of a permissive enzyme that accepts GDP-C2’epimycosamine as substrate. We aimed 
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to develop a screen to determine whether AmphDI mutants were active. To probe 
whether AmphDI mutants will accept GDP-C2’epimycosamine as a substrate, the 
deglycosylation of C2’epiAmB to form AmdeB was used as a readily accessible test 
system (Figure 8). Probing of the AmphDI mutants screening for deglycosylation 
circumvents the immediate synthesis of stable GDP-sugar donor substrates. Therefore, 
this platform will be applicable to C2’epiAmB as well as other AmB-derivatives. With 
crude lysate proved by Sherif Elshahawi from the Thorson group at the University of 
Kentucky, we used a truncated variant of AmphDI-T2 (hereon referred to as AmphDI) to 
validate its deglycosylation activity for its native substrate AmB and the desired 
compound C2’epiAmB. Initial studies were conducted in 1.7ml Eppendorf tubes using 
100µM AmB, 20mM GDP, 1mMgCl2 and 10µL (69mg/ml) of AmphDI cell lysate in 
100µL of 50mM Tris-HCl buffer were incubated at 30oC for 18hrs. After 18hrs, 100µL of 
MeOH was added to the reaction to precipitate excess protein and GDP, the resulting 
mixture was centrifuged at 4700rpm for 10mins. The supernatant was then passed 
through a 0.2-micron filter and analyzed via HPLC. These deglycosylations resulted in 
13% conversion of AmB to AmdeB based on area under the curve at 406nm; consistent 
with prior literature.2 However, AmphDI is a GT-1 family glycotransferase with 483 
amino acids.2 Therefore, thousands of AmphDI mutants will need to be screened to 
achieve adequate library coverage. Thus, development of a high-throughput screening 
platform is required to analyze the large libraries of AmphDI mutants. Unfortunately, an 
HPLC-based technique for this scale would not be efficient and has a low signal to 
noise ratio. Instead, we proposed a sensitive mass spectroscopy based plated method 
for screening AmphDI mutants.  Considering limited availability of C2’epiAmB, the 
readily available AmB was used to develop the plate-based platform. Generally, polyene 
macrolides fragment to their corresponding aglycone under standard mass 
spectroscopy conditions (ESI) making it difficult to monitor the deglycosylation reaction, 
which results in the formation of desired aglycone.  Alternatively, we identified a mild 
negative ion mode ionization method under which AmB shows as a single peak [M-H]- = 
922.47 and does not fragment into the aglycone AmdeB [M-H]- = 777.41. Thus, any 




Scheme 1. Proposed semi-synthesis of AmdeB from AmB. 
 
similar trend was observed for C2’epiAmB as it did not fragment into aglycone under 
negative ionization mode.  
To develop a plate-based method, AmB was incubated in a 96-well PCR plate under the 
previously described enzymatic conditions. After 18hrs of incubation, the reaction was 
transferred into 100µL of MeOH in a 96-well 3K MWCO plate, mixed thoroughly, and 
centrifuged at 4700rpm for 45mins. The resulting supernatant was analyzed via LCMS-
QTOF for the presence of AmB and AmdeB. The 3K MWCO was introduced to 
decrease background signal as well as remove any large proteinaceous or cellular 
debris. Our results showed by both total ion current (TIC) chromatogram and the 
corresponding mass spectrum, AmB was successfully deglycosylated with AmphDI. In 
the presence of no enzyme, only the mass corresponding to AmB is observed. Using 
C2’epiAmB as substrate resulted in no observable activity from AmphDI by LCMS Q-
TOF. Collectively, these results suggest that screening for the deglycosylation of 
C2’epiAmB would yield reliable “hits” when screening a large mutant library. However, 
deglycosylation is subject to low conversion, 13%, even using the native substrate AmB.  
The Thorson group reported the use of other GDP sugars donors to screen the activity 
of AmphDI notably GDP-mannose.2 GDP-mannose was found to be an acceptable 
substrate in the glycosylation of AmdeB using purified AmphDI enzyme. GDP-
mycosamine is the natural sugar donor in the biosynthesis of AmB and is derived from 
GDP-mannose. GDP-mannose and GDP-mycosamine have the same stereochemistry 
at each of their respective stereocenters. In comparison, GDP-C2’epimycosamine 
varies from mycosamine at only 1 stereocenter and has the same stereochemistry as 
GDP-glucose. Using the plate-based methods described earlier, we tested whether 
GDP-mannose and GDP-glucose were substrates for AmphDI using AmdeB as an 
acceptor. However, 
this would require 
the synthesis of 
aglycone acceptor 
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Figure 9. Summary of AmphDI glycosylation activity using AmdeB as substrate with several sugar 
donors. 
Wilcok et al.  we prepared >70g of the fully protected 1 (Scheme 1).23 1 was fully 
deprotected with HF-pyridine and yielded a mixture of the expected methyl ketal 
aglycone (AmdeBMK) and the target compound AmdeB.24 This mixture was then 
subjected to acidic condition to form the desired hemiketal AmdeB. With pure AmdeB in 
hand, we used AmdeB as substrate for AmphDI mediated glycosylation. We observed 
glycosylation of AmdeB with GDP-mannose but no activity with GDP-glucose using 
crude AmphDI lysate (Figure 9).2 Approximately 40% of AmdeB was converted to 
C19O-mannose amphotericin B based on analytical HPLC and corresponding a MS 
peak of 939.5 by LCMS Q-TOF. This suggest the commercially available GDP-glucose 
can serve as a surrogate for C2’epimycosamine and prevent consumption of the 
precious C2’epiAmB. Collectively, the studies show a practical assay with good 
potential to help determine active AmphDI enzymes or other glycotransferases for 
glycosylation or deglycosylation of AmdeB and GDP-glucose or C2’epiAmB 
respectively.   
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glycosylation and deglycosylation reactions, LCMS, and HPLC analysis included in this 
chapter as well as the synthesis of aglycone (AmdeB).  
Material and Methods 
Materials  
Commercial reagents were purchased from Sigma-Aldrich, Alfa Aesar, Oakwood, and 
Fischer Scientific and used without further purification unless otherwise noted. Solvents 
were purified by passage through packed columns by the method of Pangborn et al.25 
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(THF, Et2O, CH3CN, CH2Cl2, benzene, toluene, DMSO, DMF, CH3OH). Water was 
used from a Millipore (Billerica, MA) Milli-Q water purification system. Triethylamine and 
diisopropylethylamine were freshly distilled under an atmosphere of nitrogen on CaH2. 
(±)-10-Camphorsulfonic acid was recrystallized from ethyl acetate.  
General Experimental Procedures 
All reactions were performed in flame- or oven-dried glassware (60°C) under an 
atmosphere of dry nitrogen or argon unless otherwise stated. Reactions were monitored 
by analytical thin layer chromatography (TLC) on Merck silica gel 60 F254 plates 
(0.25mm) using the described solvent system. Compounds were visualized by exposure 
to UV light at 254nm or by ceric ammonium molybdate (CAM) stain by heating with a 
Varitemp heat gun. Flash column chromatography was performed using Merck silica gel 
60 (230-400mesh).  
Structural Analysis 
1H NMR spectra were recorded at ambient temperature using one of the following 
instruments: Craver B500 (500MHz). Varian Unity 500 (500MHz), Varian VXR 500 
(500MHz), or Varian Unity Inova 500NB (500MHz). Chemical shifts are reported in parts 
per million (ppm) downfield from tetramethylsilane and referenced to residual protium in 
the NMR solvent (CDCl3, δ=7.26; (CD3)2CO, δ=2.05, center line). Spectral data are 
represented as follows: chemical shift, multiplicity (s= singlet, d= doublet, t= triplet, q= 
quartet, quin= quintet, sext= sextet, dd= double of doublets, dt= doublet of triplets, ddd= 
doublet of doublet of doublets, m= multiplet, b= broad, app= apparent), coupling 
constant (J) in Hertz (Hz), and integration. 13C NMR spectra were recorded at ambient 
temperature using one of the following instruments: Craver B500 (125MHz). Varian 
Unity 500 (125MHz), or Varian VXR 500 (500MHz). Chemical shifts are reported in ppm 
downfield from tetramethylsilane and referenced to carbon resonances in the NMR 
solvent (CDCl3, δ=77.16; (CD3)2CO, δ=29.84, center line). High resolution mass spectra 
(HRMS) were acquired by Mr. Furong Sun at the University of Illinois School of 
Chemical Sciences Mass Spectrometry Laboratory. Data are reported in the form of 
m/z.  
Purification of AmB and its Derivatives 
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Large scale preparatory purification of AmB and its derivatives were carried out by 
preparative HPLC purification using an Agilent 1200 series instrument equipped with a 
Waters Sunfire Prep C18 OBD 5µm, 50x250mm column at 50ml/min with detection at 
406 and 383nm with an eluent of acetonitrile and 15mM ammonium acetate in water 
unless otherwise indicated. The purity of AmB and its derivatives was determined by 
HPLC analysis using an Sunfire C18 5µm, 4.6x150mm column or an Agilent Eclipse 
XDB-C18 5µm, 4.6x150mm column with detection at 406 and 383 nm with an eluent of 
acetonitrile and 15mM ammonium acetate unless otherwise indicated.   
Synthesis of AmdeB  
The synthesis of intermediate 1 was performed according to prior experimental 
design.23 0.9g of intermediate 1 was then azeotropically dried with benzene and placed 
under highvac overnight for a minimum of 8hrs. To a stirred solution of 1 (0.09g, 
0.519mmol, 1eq) in THF (5ml) in a polypropylene vial at 0°C was added a chilled (0°C) 
of 70% HF/pyridine complex (4.5ml) in THF:pyridine (5mL:22.5mL) and stirred for 6 
hours. The reaction was then cooled to 0°C and quenched by the addition of saturated 
aqueous sodium bicarbonate (250mL). The resulting yellow emulsion was extracted 
with methanol and rotovaped to dryness. The resulting solid was dissolved in DMSO 
and purified via preparatory HPLC. This resulted in a mixture (0.310g, .390mmol, 75%) 
of desired amphoternolide methyl ketal (AmdeBMK) and the end-product AmdeB. This 
mixture was carried forward without purification or characterization. To a stirred solution 
of 124mg (.156mmol, 1 eq) of the AmdeBMK mixture suspended in THF:H2O (2:1) at 
room temperature, 146mg of (±)-10-camphorsulfonic acid (.628mmol, 5eq) was added 
and allowed to stir for 30mins. After 30mins, 0.5ml triethylamine (25eq) was added into 
the solution and was thoroughly mixed for 10mins. The solution was then diluted with 
DMSO and purified by HPLC. 1H NMR correlated from work previously described and 
had an LCMS mass of 777.4 amu.24      
Expression and Isolation of AmphDI 
Plasmid pCST576 (AmphD1-T2)2 was transformed into E. coli BL21 (DE3) (NEB) and 
single isolates used as a source for seed culture inoculation. LB medium (1 L) 
supplemented with kanamycin (50 μg mL-1) was inoculated with 0.1 % (v/v) of an 
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overnight seed culture harboring the plasmid pCST576 and incubated at 37 °C with 
shaking (225 rpm) to an OD600 of ~ 0.7. Cultures were induced using a final 
concentration of 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and growth 
continued for an additional 16 h at 20°C. The culture was centrifuged (5,000 xg, 15 min, 
4°C) the recovered cell pellet resuspended in 25 mL lysis buffer (50 mM Tris Cl, 100 
mM NaCl, 10% glycerol, pH 8.0) and lysed on ice using a sonicator (VirSonic 475; 
Virtis) equipped with a microtip (100W, 10 × 30s pulses, 2 min between pulses). Cell 
debris was removed via centrifugation (18,000 xg, 50 min, 4°C) and subsequently 
passed through a 0.22 μM filter. The concentration of the crude lysate (total protein) 
was 89 mg/ml, based on A280, in a total volume of 25 ml. The lysate was drop frozen as 
aliquots in liquid nitrogen and the corresponding stored at -80°C. 
Deglycosylation using AmphDI  
100µM AmB (as determined by UV-Vis), 20mM GDP (Sigma), 1mMgCl2 and 10µL 
(69mg/ml) of AmphDI cell lysate were place into a 96-well PCR plate with the remaining 
volume filled to 100µL of 50mM Tris-HCl buffer and were incubated at 30oC for 18hrs. A 
control reaction was conducted with no enzyme added under conditions identical as 
described. This reaction was performed in technical triplicate. After 18hrs of incubation, 
the reaction was transferred into 100µL of MeOH in a 96-well 3K MWCO plate (Pall 
Corp. AK Omega™ 350µL well plates), mixed thoroughly, and centrifuged at 
4700rpm for 45mins. The resulting solution was submitted for LCMS-QTOF at the 









Figure 11. HPLC chromatogram of AmdeB at 406nm and mass spectrum of AmdeB. 
 
 
Figure 10. Total ion current of mass corresponding to the exact mass of AmB (top) and AmdeB 
(bottom) with AmphDI present. 
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Glycosylation using AmphDI 
100µM AmdeB (as determined by UV-Vis), 2mM GDP-sugar donor (Sigma), 1mMgCl2 
and 10µL (69mg/ml) of AmphDI cell lysate were place into a 96-well PCR plate with the 
remaining volume filled to 100µL of 50mM Tris-HCl buffer and were incubated at 30oC 
for 18hrs. A control reaction was conducted with no enzyme added under conditions 
identical as described. This reaction was performed in technical triplicate. After 18hrs of 
incubation, the reaction was transferred into 100µL of MeOH in a 96-well 3K MWCO 
plate (Pall Corp. AK Omega™ 350µL well plates), mixed thoroughly, and centrifuged 






Figure 12. Top: HPLC chromatogram (406nm) of the glycosylation of AmdeB with GDP-
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